Publications

• Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease.
  Blood Adv Volume: 9 Page(s): 955 - 965
  03/11/2025 Authors: Walters MC; Eapen M; Liu Y; El Rassi F; Waller EK; Levine JE; Strouse JJ; Antin JH; Parikh SH; Bakshi N
• Real-World Outcomes of Relapsed/Refractory Core-Binding Factor Acute Myeloid Leukemia: A COMMAND Registry Study.
  Am J Hematol
  03/10/2025 Authors: Rojek AE; McCormick BJ; Cwykiel J; Odetola O; Abaza Y; Nai N; Foucar CE; Achar RK; Shallis RM; Bradshaw D
• Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality: The ECOG-ACRIN EA9131 Trial.
  JAMA Oncol Volume: 11 Page(s): 400 - 407
  02/27/2025 Authors: Jillella AP; Lee SJ; Altman JK; Luger SM; Tallman MS; Foran JM; Bradshaw D; Law LY; Bryan LJ; Abou Zahr A
• Incidence of engraftment syndrome with and without budesonide prophylaxis in patients with multiple myeloma undergoing autologous stem cell transplant.
  Support Care Cancer Volume: 33 Page(s): 213
  02/22/2025 Authors: Gloe L; Rakestraw A; Daniels S; Chen X; Kota V; Clemmons AB
• Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
  J Clin Oncol Volume: 43 Page(s): 558 - 566
  02/10/2025 Authors: Roloff GW; Aldoss I; Kopmar NE; Lin C; Dekker SE; Gupta VK; O'Connor TE; Jeyakumar N; Muhsen IN; Valtis Y
• The Role of Ferritin and Folate in Determining Stem Cell Collection for Autologous Stem Cell Transplant in Multiple Myeloma.
  Hematol Rep Volume: 17
  01/24/2025 Authors: Weeks CJ; Mian M; Stokes M; Gold M; Shah A; Vuppala R; Kim KJ; Simon AB; Cortes J; Jillela A
• Identification of a distinctive immunogenomic gene signature in stage-matched colorectal cancer.
  J Cancer Res Clin Oncol Volume: 151 Page(s): 9
  12/14/2024 Authors: Ahluwalia P; Mondal AK; Vashisht A; Singh H; Alptekin A; Ballur K; Omar N; Ahluwalia M; Jones K; Barrett A
• Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.
  Blood Adv Volume: 8 Page(s): 6139 - 6147
  12/10/2024 Authors: Aldoss I; Roloff GW; Faramand R; Kopmar NE; Lin C; Advani AS; Dekker SE; Gupta VK; O'Connor TE; Jeyakumar N
• Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A multi-institutional study.
  Am J Hematol Volume: 99 Page(s): 2388 - 2391
  12/01/2024 Authors: Badar T; Narra R; Mims AS; Heckman MG; Shallis RM; Fahad S; Hunter C; Kota V; Othman TA; Jonas B
• Prognostic impact of 'multi-hit' versus 'single-hit' TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases.
  Haematologica Volume: 109 Page(s): 3533 - 3542
  11/01/2024 Authors: Badar T; Nanaa A; Atallah E; Shallis RM; Craver EC; Li Z; Goldberg AD; Saliba AN; Patel A; Bewersdorf JP
• Identifying Candidates for Effective Utilization of Stored Autologous PBSCs in Salvage Transplantation for Multiple Myeloma: Who Benefits Most?
  Hematol Rep Volume: 16 Page(s): 479 - 486
  07/12/2024 Authors: Keruakous AR; Walker L; Denlinger M; Mian MAH; Bradshaw D; Kota VK; Jillella AP
• Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75years and older with acute myeloid leukemia: Real-world data from eight US academic centers.
  Am J Hematol Volume: 99 Page(s): 606 - 614
  04/01/2024 Authors: Abaza Y; Winer ES; Murthy GSG; Shallis RM; Matthews AH; Badar T; Geramita EM; Kota VK; Swaroop A; Doukas P
• Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
  Blood Cancer J Volume: 14 Page(s): 32
  02/20/2024 Authors: Badar T; Nanaa A; Atallah E; Shallis RM; Guilherme SDCC; Goldberg AD; Saliba AN; Patel A; Bewersdorf JP; DuVall AS
• Exploring treatment decision-making in chronic myeloid leukemia in chronic phase.
  Front Oncol Volume: 14 Page(s): 1369246
  01/01/2024 Authors: Andorsky D; Kota V; Sweet K
• Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia.
  Cancer Volume: 130 Page(s): 287 - 299
  01/01/2024 Authors: Efficace F; Cottone F; Yanez B; Kota V; Castagnetti F; Caocci G; Bonifacio M; Patriarca A; Capodanno I; Miggiano MC
• Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.
  Blood Adv Volume: 7 Page(s): 7494 - 7500
  12/26/2023 Authors: Altman JK; Zuckerman T; Koprivnikar J; McCloskey J; Kota V; Keng M; Frankfurt O; Abaza Y; Bixby DL; Emadi A
• Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia.
  JAMA Netw Open Volume: 6 Page(s): e2347950
  12/01/2023 Authors: Winn AN; Atallah E; Cortes J; Deininger MWN; Kota V; Larson RA; Moore JO; Mauro MJ; Oehler VG; Pinilla-Ibarz J
• Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study.
  Haematologica Volume: 108 Page(s): 3454 - 3459
  12/01/2023 Authors: Cortes JE; Lipton JH; Kota V; Castagnetti F; Assouline S; Brmmendorf TH; Leip E; Viqueira A; Gambacorti-Passerini C
• Industry's role in HIV, hepatitis B, and hepatitis C exclusion in AML and MDS clinical trials.
  Hematology Volume: 28 Page(s): 2254558
  12/01/2023 Authors: Anwar T; Malhotra S; Mian MAH; Anwar T; Kota V; Shoukier M
• Ethno-demographic disparities in humoral responses to the COVID-19 vaccine among healthcare workers.
  J Med Virol Volume: 95 Page(s): e29067
  09/01/2023 Authors: Ahluwalia P; Vashisht A; Singh H; Sahajpal NS; Mondal AK; Jones K; Farmaha J; Bloomquist R; Carlock CM; Fransoso D
• Hematological Adverse Events with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review with Meta-Analysis.
  Cancers (Basel) Volume: 15
  08/31/2023 Authors: Kronick O; Chen X; Mehra N; Varmeziar A; Fisher R; Kartchner D; Kota V; Mitchell CS
• Optical Genome Mapping: Integrating Structural Variations for Precise Homologous Recombination Deficiency Score Calculation.
  Genes (Basel) Volume: 14
  08/25/2023 Authors: Sahajpal NS; Mondal AK; Vashisht A; Singh H; Pang AWC; Saul D; Nivin O; Hilton B; DuPont BR; Kota V
• Clinical Utility of Optical Genome Mapping and 523-Gene Next Generation Sequencing Panel for Comprehensive Evaluation of Myeloid Cancers.
  Cancers (Basel) Volume: 15
  06/16/2023 Authors: Sahajpal NS; Mondal AK; Singh H; Vashisht A; Ananth S; Saul D; Hastie AR; Hilton B; DuPont BR; Savage NM
• Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community Setting.
  Clin Lymphoma Myeloma Leuk Volume: 23 Page(s): e222 - e231
  05/01/2023 Authors: Gershon A; Ma E; Xu T; Montez M; Naqvi K; Ku G; Cheng WW-H; Flahavan EM; Kota V; Greenwald DR
• A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia.
  Cancer Chemother Pharmacol Volume: 91 Page(s): 441 - 446
  05/01/2023 Authors: Montesinos P; Kota V; Brandwein J; Bousset P; Benner RJ; Vandendries E; Chen Y; McMullin MF
• Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
  Leukemia Volume: 37 Page(s): 799 - 806
  04/01/2023 Authors: Badar T; Atallah E; Shallis R; Saliba AN; Patel A; Bewersdorf JP; Grenet J; Stahl M; Duvall A; Burkart M
• Economic Impact of Transformation to Acute Myeloid Leukemia Among Actively Managed Patients with Higher-Risk Myelodysplastic Syndromes in the United States.
  Adv Ther Volume: 40 Page(s): 1655 - 1669
  04/01/2023 Authors: Kota V; Ogbonnaya A; Farrelly E; Schroader BK; Raju A; Kristo F; Dalal M
• Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia.
  Cancer Volume: 129 Page(s): 934 - 945
  03/15/2023 Authors: Badar T; Litzow MR; Shallis RM; Patel A; Saliba AN; Burkart M; Bewersdorf JP; Stahl M; De Camargo Correia GS; Guru Murthy GS
• Immune Factors Drive Expression of SARS-CoV-2 Receptor Genes Amid Sexual Disparity.
  Viruses Volume: 15
  02/28/2023 Authors: Vashisht A; Ahluwalia P; Mondal AK; Singh H; Sahajpal NS; Fulzele S; Kota V; Gahlay GK; Kolhe R
• Clinical Validation and Diagnostic Utility of Optical Genome Mapping for Enhanced Cytogenomic Analysis of Hematological Neoplasms.
  J Mol Diagn Volume: 24 Page(s): 1279 - 1291
  12/01/2022 Authors: Sahajpal NS; Mondal AK; Tvrdik T; Hauenstein J; Shi H; Deeb KK; Saxe D; Hastie AR; Chaubey A; Savage NM
• Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes.
  Future Oncol Volume: 18 Page(s): 4017 - 4029
  11/01/2022 Authors: Kota V; Ogbonnaya A; Farrelly E; Schroader BK; Raju A; Kristo F; Dalal M
• Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia.
  Haematologica Volume: 107 Page(s): 2641 - 2649
  11/01/2022 Authors: Flynn KE; Atallah E; Lin L; Shah NP; Silver RT; Larson RA; Panilla-Ibarz J; Thompson JE; Oehler VG; Radich JP
• CML-413 Efficacy and Safety of Bosutinib Versus Imatinib in US Patients With Newly Diagnosed Chronic Myeloid Leukemia After 5-Years Follow-Up in the BFORE Trial.
  Clin Lymphoma Myeloma Leuk Volume: 22 Suppl 2 Page(s): S296 - S297
  10/01/2022 Authors: Kota V; Deininger MW; Mendler J; Shen W; Goldmann E; Cortes JE
• CT-448 Academic Center Outreach to Community Practices Increases Transplant Referrals and Possibly Reduces Racial Disparities.
  Clin Lymphoma Myeloma Leuk Volume: 22 Suppl 2 Page(s): S445
  10/01/2022 Authors: Kota V; Bryan L; Chauhan A; Mian M; Keruakous A; Cortes J; Jillella A
• CML-475 Real-World Treatment Patterns Among Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Cycling Through Multiple Tyrosine Kinase Inhibitors (TKIs) in the United States (US).
  Clin Lymphoma Myeloma Leuk Volume: 22 Suppl 2 Page(s): S300 - S301
  10/01/2022 Authors: Kota V; Maegawa R; Latremouille-Viau D; Jadhav K; Rossi C; Gurin A; Lorga
• Cross-Domain Text Mining to Predict Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.
  Cancers (Basel) Volume: 14
  09/26/2022 Authors: Mehra N; Varmeziar A; Chen X; Kronick O; Fisher R; Kota V; Mitchell CS
• Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.
  Volume: 36 Page(s): 1825 - 1833
  07/01/2022 Authors: Brmmendorf TH; Cortes JE; Milojkovic D; Gambacorti-Passerini C; Clark RE; le Coutre P; Garcia-Gutierrez V; Chuah C; Kota V; Lipton JH
• PARIS and SPARTA: Finding the Achilles' Heel of SARS-CoV-2.
  mSphere Volume: 7 Page(s): e0017922
  06/29/2022 Authors: Simon V; Kota V; Bloomquist RF; Hanley HB; Forgacs D; Pahwa S; Pallikkuth S; Miller LG; Schaenman J; Yeaman MR
• Patient preferences for frontline therapies for Philadelphia chromosome-positive acute lymphoblastic leukemia: a discrete choice experiment.
  Future Oncol Volume: 18 Page(s): 2075 - 2085
  06/01/2022 Authors: Ashaye A; Thomas C; Dalal M; Kota V; Krucien N; Sae-Hau M; Weiss E; Campbell S; Marsh K
• Clinical validation of a multiplex PCR-based detection assay using saliva or nasopharyngeal samples for SARS-Cov-2, influenza A and B.
  Sci Rep Volume: 12 Page(s): 3480
  03/03/2022 Authors: Sahajpal NS; Mondal AK; Ananth S; Njau A; Jones K; Ahluwalia P; Oza E; Ross TM; Kota V; Kothandaraman A
• Clinical and molecular assessment of an onco-immune signature with prognostic significance in patients with colorectal cancer.
  Cancer Med Volume: 11 Page(s): 1573 - 1586
  03/01/2022 Authors: Ahluwalia P; Mondal AK; Ahluwalia M; Sahajpal NS; Jones K; Jilani Y; Gahlay GK; Barrett A; Kota V; Rojiani AM
• Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors.
  J Natl Cancer Inst Volume: 114 Page(s): 160 - 164
  01/11/2022 Authors: Schoenbeck KL; Atallah E; Lin L; Weinfurt KP; Cortes J; Deininger MWN; Kota V; Larson RA; Mauro MJ; Oehler VG
• Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with acute myeloid leukemia meeting ineligibility criteria for high intensity chemotherapy.
  Leuk Lymphoma Volume: 63 Page(s): 131 - 141
  01/01/2022 Authors: Li S; Ji Y; Peng Y; Kota V; Kim C
• Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosomepositive leukemias.
  Leuk Res Volume: 111 Page(s): 106690
  12/01/2021 Authors: Kota V; Brmmendorf TH; Gambacorti-Passerini C; Lipton JH; Kim D-W; An F; Leip E; Crescenzo RJ; Ferdinand R; Cortes JE
• A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia.
  Leuk Lymphoma Volume: 62 Page(s): 3192 - 3203
  12/01/2021 Authors: Sweet K; Bhatnagar B; Dhner H; Donnellan W; Frankfurt O; Heuser M; Kota V; Liu H; Raffoux E; Roboz GJ
• Natural Killer Cells and Dendritic Cells: Expanding Clinical Relevance in the Non-Small Cell Lung Cancer (NSCLC) Tumor Microenvironment.
  Cancers (Basel) Volume: 13
  08/11/2021 Authors: Ahluwalia P; Ahluwalia M; Mondal AK; Sahajpal NS; Kota V; Rojiani MV; Kolhe R
• Clinical Validation of a Sensitive Test for Saliva Collected in Healthcare and Community Settings with Pooling Utility for Severe Acute Respiratory Syndrome Coronavirus 2 Mass Surveillance.
  J Mol Diagn Volume: 23 Page(s): 788 - 795
  07/01/2021 Authors: Sahajpal NS; Mondal AK; Ananth S; Njau A; Ahluwalia P; Kota V; Caspary K; Ross TM; Farrell M; Shannon MP
• Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates.
  Leuk Lymphoma Volume: 62 Page(s): 1730 - 1739
  07/01/2021 Authors: Atallah EL; Sadek I; Maegawa R; Cao X; Latremouille-Viau D; Pivneva I; Rossi C; Guerin A; Kota V
• SalivaSTAT: Direct-PCR and Pooling of Saliva Samples Collected in Healthcare and Community Setting for SARS-CoV-2 Mass Surveillance.
  Diagnostics (Basel) Volume: 11
  05/19/2021 Authors: Sahajpal NS; Mondal AK; Ananth S; Njau A; Ahluwalia P; Newnam G; Lozoya-Colinas A; Hud NV; Kota V; Ross TM
• Prognostic and therapeutic implications of extracellular matrix associated gene signature in renal clear cell carcinoma.
  Sci Rep Volume: 11 Page(s): 7561
  04/07/2021 Authors: Ahluwalia P; Ahluwalia M; Mondal AK; Sahajpal N; Kota V; Rojiani MV; Rojiani AM; Kolhe R
• Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.
  Cancers (Basel) Volume: 13
  04/01/2021 Authors: Mohanavelu P; Mutnick M; Mehra N; White B; Kudrimoti S; Hernandez Kluesner K; Chen X; Nguyen T; Horlander E; Thenot H
• Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia.
  JCO Oncol Pract Volume: 17 Page(s): e497 - e505
  04/01/2021 Authors: Jillella AP; Arellano ML; Gaddh M; Langston AA; Heffner LT; Winton EF; McLemore ML; Zhang C; Caprara CR; Simon KS
• Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia.
  Leuk Lymphoma Volume: 62 Page(s): 669 - 678
  03/01/2021 Authors: Efficace F; Iurlo A; Patriarca A; Stagno F; Bee P-C; Ector G; Capodanno I; Elena C; Bonifacio M; Blijlevens NMA
• Epidemiology, Staging, and Management of Multiple Myeloma.
  Med Sci (Basel) Volume: 9
  01/20/2021 Authors: Padala SA; Barsouk A; Barsouk A; Rawla P; Vakiti A; Kolhe R; Kota V; Ajebo GH
• Immunogenomic Gene Signature of Cell-Death Associated Genes with Prognostic Implications in Lung Cancer.
  Cancers (Basel) Volume: 13
  01/05/2021 Authors: Ahluwalia P; Ahluwalia M; Mondal AK; Sahajpal N; Kota V; Rojiani MV; Rojiani AM; Kolhe R
• Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
  JAMA Oncol Volume: 7 Page(s): 42 - 50
  01/01/2021 Authors: Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang M-J; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ
• Optimizing management of acute leukemia in community centers and when to refer.
  Hematology Am Soc Hematol Educ Program Volume: 2020 Page(s): 123 - 128
  12/04/2020 Authors: Jillella AP; Cortes JE; Kota VK
• Infections of the lung: a predictive, preventive and personalized perspective through the lens of evolution, the emergence of SARS-CoV-2 and its pathogenesis.
  EPMA J Volume: 11 Page(s): 581 - 601
  12/01/2020 Authors: Ahluwalia P; Ahluwalia M; Vaibhav K; Mondal A; Sahajpal N; Islam S; Fulzele S; Kota V; Dhandapani K; Baban B
• Role of indoleamine 2,3-dioxygenase in acute myeloid leukemia.
  Future Oncol Volume: 16 Page(s): 3085 - 3094
  12/01/2020 Authors: Sobash PT; Kolhe R; Karim NA; Guddati AK; Jillella A; Kota V
• Effective optimization of SARS-CoV-2 laboratory testing variables in an era of supply chain constraints.
  Future Microbiol Page(s): 1483 - 1487
  11/12/2020 Authors: S Sahajpal N; Mondal AK; Njau A; Ananth S; Jones K; Ahluwalia PK; Ahluwalia M; Jilani Y; Chaubey A; Hegde M
• Proposal of RT-PCR-Based Mass Population Screening for Severe Acute Respiratory Syndrome Coronavirus 2 (Coronavirus Disease 2019).
  J Mol Diagn Volume: 22 Page(s): 1294 - 1299
  10/01/2020 Authors: Sahajpal NS; Mondal AK; Njau A; Ananth S; Jones K; Ahluwalia PK; Ahluwalia M; Jilani Y; Chaubey A; Hegde M
• Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors.
  J Clin Med Volume: 9
  05/20/2020 Authors: Kong JH; Winton EF; Heffner LT; Gaddh M; Hill B; Neely J; Hatcher A; Joseph M; Arellano M; El-Rassi F
• Analysis of outcomes in hospitalized pregnant patients with acute myeloid leukemia.
  Volume: 10 Page(s): 68 - 75
  01/01/2020 Authors: Patel SJ; Ajebo G; Kota V; Guddati AK
• Outcomes of hospitalized patients with myocardial infarction and immune thrombocytopenic purpura: a cross sectional study over 15 years.
  Volume: 10 Page(s): 210 - 216
  01/01/2020 Authors: Patel SJ; Ajebo G; Kota V; Guddati AK
• Management of a 75-Year-Old Lady with Refractory Chronic Myelogenous Leukemia.
  Case Rep Oncol Volume: 13 Page(s): 534 - 537
  01/01/2020 Authors: Sobash PT; Guddati AK; Kota V
• Thyroiditis: A Rare Manifestation of Enasidenib-Induced Differentiation Syndrome.
  Case Rep Oncol Volume: 13 Page(s): 583 - 587
  01/01/2020 Authors: Annamaraju P; Gopishetty S; Goparaju N; Beasey M; Kota V; Guddati AK
• Age and race distribution in patients in phase III oncology clinical trials.
  Am J Transl Res Volume: 12 Page(s): 5977 - 5983
  01/01/2020 Authors: Gopishetty S; Kota V; Guddati AK
• Clinical performance and utility of a comprehensive next-generation sequencing DNA panel for the simultaneous analysis of variants, TMB and MSI for myeloid neoplasms.
  PLoS One Volume: 15 Page(s): e0240976
  01/01/2020 Authors: Sahajpal NS; Mondal AK; Ananth S; Njau A; Ahluwalia P; Jones K; Ahluwalia M; Okechukwu N; Savage NM; Kota V
• Trends in the crossover of patients in phase III oncology clinical trials in the USA.
  Ecancermedicalscience Volume: 14 Page(s): 1142
  01/01/2020 Authors: Yeh J; Gupta S; Patel SJ; Kota V; Guddati AK
• ERRATUM: Managing acute promyelocytic leukemia in patients belonging to the Jehovah's Witness congregation.
  Hematol Rep Volume: 11 Page(s): 8395
  11/29/2019 Authors: Jillella AP; Arellano ML; Heffner LT; Gaddh M; Langston AA; Khoury HJ; Mangaonkar A; Kota VK
• Identification and Clinical Validation of a Novel 4 Gene-Signature with Prognostic Utility in Colorectal Cancer.
  Int J Mol Sci Volume: 20
  08/05/2019 Authors: Ahluwalia P; Mondal AK; Bloomer C; Fulzele S; Jones K; Ananth S; Gahlay GK; Heneidi S; Rojiani AM; Kota V
• Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Tyrosine Kinase Inhibitor Therapy Cessation.
  Clin Lymphoma Myeloma Leuk Volume: 19 Page(s): 480 - 487
  08/01/2019 Authors: Kota V; Atallah E
• Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with ALL.
  Leuk Lymphoma Volume: 60 Page(s): 1462 - 1468
  06/01/2019 Authors: Kim C; Molony JT; Chia VM; Kota VK; Katz AJ; Li S
• Availability of all-trans retinoic acid and support systems for management of acute promyelocytic leukemia in Michigan and Louisiana, USA.
  Hematol Rep Volume: 11 Page(s): 7896
  05/23/2019 Authors: Bolds SL; Hassan SMK; Caprara CR; Debragga S; Simon KS; Karkhanis P; Gandhi A; Jillella AP; Kota V
• Patients' perspectives on the definition of cure in chronic myeloid leukemia.
  Leuk Res Volume: 80 Page(s): 40 - 42
  05/01/2019 Authors: Flynn KE; Mauro MJ; George G; Hinman A; Baim A; Kota V; Larson RA; Lipton JH; Thompson JE; Wadleigh M
• A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent.
  Leuk Res Volume: 78 Page(s): 45 - 51
  03/01/2019 Authors: Bell JA; Galaznik A; Farrelly E; Blazer M; Murty S; Ogbonnaya A; Eaddy M; Fram RJ; Faller DV; Kota VK
• A Case of Chronic Myelogenous Leukemia Occurring in a Patient Treated for Essential Thrombocythemia.
  Am J Case Rep Volume: 20 Page(s): 10 - 14
  01/03/2019 Authors: Hassankrishnamurthy S; Mody MD; Kota VK
• Rectovaginal Fistula as a Complication of Fecal Management System.
  J Investig Med High Impact Case Rep Volume: 7 Page(s): 2324709619869368
  01/01/2019 Authors: Butts E; Padala SA; Vakiti A; Kota V
• Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review.
  J Hematol Oncol Volume: 11 Page(s): 143
  12/27/2018 Authors: Cortes JE; Apperley JF; DeAngelo DJ; Deininger MW; Kota VK; Rousselot P; Gambacorti-Passerini C
• Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial
  Volume: 132
  11/29/2018 Authors: Deininger MW; Kota V; Lipton JH; Milojkovic D; Garcia Gutierrez V; Leip E; Nick S; Hochhaus A; Gambacorti-Passerini C; Cortes JE
• TREATMENT OF VENOUS THROMBOEMBOLISM DURING INDUCTION CHEMOTHERAPY IN PATIENTS WITH ACUTE LEUKEMIA: A SINGLE CENTER EXPERIENCE
  Volume: 93 Page(s): E51 - E51
  09/01/2018 Authors: Patel B; Cheng E; McLemore M; Arellano M; Heffner LT; Winton EF; Bodo I; Langston A; Kota V; Gaddh M
• The OPTIC Study: A Multicenter, Randomized, Phase 2 Trial to Evaluate Three Starting Doses of Ponatinib With Response-Based Dose Reduction in Patients with Chronic Phase Chronic Myeloid Leukemia Resistant to Prior Tyrosine Kinase Therapy
  Volume: 18 Page(s): S228 - S229
  09/01/2018 Authors: Garcia Gutierrez V; Deininger MW; Baer MR; Kota VK; Akard L; Chuah C; Guerci-Bresler A; Carlos Hernandez-Boluda J; Neumann F; Xu J
• Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States.
  Leuk Res Volume: 71 Page(s): 27 - 33
  08/01/2018 Authors: Bell JA; Galaznik A; Farrelly E; Blazer M; Murty S; Ogbonnaya A; Eaddy M; Fram RJ; Faller DV; Kota V
• Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease.
  Bone Marrow Transplant Volume: 53 Page(s): 826 - 831
  07/01/2018 Authors: Khoury HJ; Langston AA; Kota VK; Wilkinson JA; Pusic I; Jillella A; Bauer S; Kim AS; Roberts D; Al-Kadhimi Z
• Rhabdomyolysis Following Initiation of Antiviral Therapy with Oseltamivir.
  Am J Case Rep Volume: 19 Page(s): 673 - 677
  06/11/2018 Authors: Puttagunta H; Alghsoon S; Regula P; Hassankrishnamurthy S; Kota VK
• The global problem of early deaths in acute promyelocytic leukemia: A strategy to decrease induction mortality in the most curable leukemia.
  Blood Rev Volume: 32 Page(s): 89 - 95
  03/01/2018 Authors: Jillella AP; Kota VK
• Utility Of A Comprehensive Cost-Effective Targeted DNA/RNA Panel (170 Genes) On A Next Generation Sequencing (NGS) Platform In Evaluation Of Melanoma For Tumor Specific Information, Microsatellite Instability (MSI) And Calculating The Overall Tumor Mutation Burden (TMB)
  Volume: 31 Page(s): 201 - 201
  03/01/2018 Authors: Kolhe R; MOndal A; Pundkar C; Kota V; Chaubey A
• Utility Of A Comprehensive Cost-Effective Targeted DNA/RNA Panel (170 Genes) On A Next Generation Sequencing (NGS) Platform In Evaluation Of Melanoma For Tumor Specific Information, Microsatellite Instability (MSI) And Calculating The Overall Tumor Mutation Burden (TMB)
  Volume: 98 Page(s): 201 - 201
  03/01/2018 Authors: Kolhe R; MOndal A; Pundkar C; Kota V; Chaubey A
• Outcomes after Sequential Tyrosine Kinase Inhibitors Treatment in Chronic Phase Chronic Myeloid Leukemia
  Volume: 130
  12/07/2017 Authors: Kong JH; Winton EF; Heffner L; Gaddh M; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK
• Outcomes of Chronic Phase Chronic Myeloid Leukemia (CP-CML) after Sequential Treatment with Tyrosine Kinase Inhibitors (TKI)
  Volume: 130
  12/07/2017 Authors: Kong JH; Winton EF; Heffner L; Gaddh M; Hill B; Arellano ML; El-Rassi F; Kim A; Kota V
• Incidence and Predictors of Left Ventricular Dysfunction Among Acute Myeloid Leukemia Patients
  Volume: 130
  12/07/2017 Authors: Almuwaqqat Z; Gaddh M; Schlafer D; Hutcherson D; Arellano ML; Parashar S; Kota V
• Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective Switch From Second-Generation Tyrosine Kinase Inhibitor to Imatinib.
  Clin Lymphoma Myeloma Leuk Volume: 17 Page(s): e71 - e73
  12/01/2017 Authors: Kota VK; Kong JH; Arellano M; El Rassi F; Gaddh M; Heffner LT; Winton EF; Jillella AP; McLemore ML; Khoury HJ
• A novel immunohistochemical score to predict early mortality in acute myeloid leukemia patients based on indoleamine 2,3 dioxygenase expression.
  Sci Rep Volume: 7 Page(s): 12892
  10/16/2017 Authors: Mangaonkar A; Mondal AK; Fulzule S; Pundkar C; Park EJ; Jillella A; Kota V; Xu H; Savage NM; Shi H
• The safety of Bosutinib for the treatment of chronic myeloid leukemia.
  Expert Opin Drug Saf Volume: 16 Page(s): 1203 - 1209
  10/01/2017 Authors: Kong JH; Khoury HJ; Kim AS; Hill BG; Kota V
• Managing acute promyelocytic leukemia in patients belonging to the Jehovah's Witness congregation.
  Hematol Rep Volume: 9 Page(s): 7083
  09/26/2017 Authors: Jillella AP; Arellano ML; Heffner LT; Gaddh M; Langston AA; Khoury HJ; Mangoankar A; Kota VK
• Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
  Cancer Volume: 123 Page(s): 2482 - 2488
  07/01/2017 Authors: Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A
• 5-YEAR EFFICACY OF DASATINIB AND IMATINIB IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH DOSE MODIFICATIONS FROM DASISION
  Volume: 102 Page(s): 433 - 433
  06/26/2017 Authors: Hochhaus A; Jabbour E; Kantarjian H; Guilhot F; Kota V; Hughes TP; Shelat S; Li L; Cortes JE
• Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.
  Future Oncol Volume: 13 Page(s): 395 - 407
  02/01/2017 Authors: Winton EF; Kota V
• Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients.
  J Oncol Pharm Pract Volume: 23 Page(s): 10 - 17
  01/01/2017 Authors: Hartranft ME; Clemmons AB; DeRemer DL; Kota V
• Rhabdomyolysis Following Initiation of Posaconazole Use for Antifungal Prophylaxis in a Patient With Relapsed Acute Myeloid Leukemia: A Case Report.
  J Investig Med High Impact Case Rep Volume: 5 Page(s): 2324709617690747
  01/01/2017 Authors: Mody MD; Ravindranathan D; Gill HS; Kota VK
• Outcomes of Chronic Phase Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitors Dose-Reductions
  Volume: 128
  12/02/2016 Authors: Kong JH; Khoury HJ; Winton EF; Heffner LT; Gaddh M; Arellano M; El-Rassi F; Kim AS; Jillella A; Bodo I
• Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis.
  Biol Blood Marrow Transplant Volume: 22 Page(s): 1348 - 1356
  08/01/2016 Authors: Ustun C; Gotlib J; Popat U; Artz A; Litzow M; Reiter A; Nakamura R; Kluin-Nelemans HC; Verstovsek S; Gajewski J
• Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
  Clin Lymphoma Myeloma Leuk Volume: 16 Page(s): 466 - 471.e1
  08/01/2016 Authors: DeFilipp Z; Langston AA; Chen Z; Zhang C; Arellano ML; El Rassi F; Flowers CR; Kota VK; Al-Kadhimi Z; Veldman R
• Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant.
  J Oncol Pharm Pract Volume: 22 Page(s): 416 - 422
  06/01/2016 Authors: Clark SM; Clemmons AB; Schaack L; Garren J; DeRemer DL; Kota VK
• DECREASING EARLY DEATHS IN ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN AN ACADEMIC CENTER IN THE US BY USING A SIMPLIFIED TREATMENT ALGORITHM AND DEDICATED APL EXPERTS
  Volume: 101 Page(s): 675 - 676
  06/01/2016 Authors: Jillella A; Mody M; Harpaul G; Arellano M; Khoury H; Al-Kadhimi Z; McLemore M; Winton E; Gaddh M; Heffner L
• Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant
  JOURNAL OF ONCOLOGY PHARMACY PRACTICE Volume: 22 Page(s): 416 - 422
  06/01/2016 Authors: Clark SM; Clemmons AB; Schaack L; Garren J; DeRemer DL; Kota VK
• Costs associated with induction chemotherapy in adult acute myeloid leukemia (AML) managed in a tertiary care specialized unit.
  Volume: 34
  05/20/2016 Authors: Gleason S; Howard DH; Liu Y; Goldstein DA; Arellano ML; Jillella AP; Gaddh M; Kota V; Winton EF; Heffner LT
• Early Allogeneic Stem Cell Transplantation Appears to Improve Outcomes in Adult T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) Patients: A Multi-Institutional Review
  Volume: 22 Page(s): S202 - S202
  03/01/2016 Authors: Hathaway AR; Peker D; Jackson BE; Kota VK; Shah BD; Zhang L; Jillella AP; Arellano M; Heffner LT; Erba HP
• Tailored Post-Transplant Maintenance with Tyrosine Kinase Inhibitors for High-Risk Philadelphia Chromosome-Positive Leukemia
  Volume: 22 Page(s): S313 - S313
  03/01/2016 Authors: DeFilipp Z; Langston AA; Kota VK; Al-Kadhimi Z; Jillella AP; Waller EK; Khoury HJ
• Prognostic value of complete remission with superior platelet counts in acute myeloid leukemia.
  J Community Support Oncol Volume: 14 Page(s): 66 - 71
  02/01/2016 Authors: Mangaonkar A; Xu H; Mohsin J; Mansour J; Chintalapally R; Keen R; Mondal AK; DeRemer D; Clemmons AB; Clark SM
• Recurrent Parotid Carcinosarcoma in an Asymptomatic Patient.
  J Investig Med High Impact Case Rep Volume: 4 Page(s): 2324709616676590
  01/01/2016 Authors: Mansour J; Mangaonkar A; Kota V
• Complete Remission of Acute Myeloid Leukemia following Cisplatin Based Concurrent Therapy with Radiation for Squamous Cell Laryngeal Cancer.
  Case Rep Hematol Volume: 2016 Page(s): 8581421
  01/01/2016 Authors: Mody MD; Gill HS; Higgins KA; Saba NF; Kota VK
• Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Who Switch to Imatinib Following Optimal Response to Second Generation Tyrosine Kinase Inhibitors
  Volume: 126
  12/03/2015 Authors: Kota VK; Winton EF; Arellano M; Jillella A; McLemore ML; El Rassi F; Khoury HJ
• Multi-Institution Review of Adult Early T-Cell Precursor Acute Lymphoblastic Leukemia/Lymphoma (ETP-ALL)
  Volume: 126
  12/03/2015 Authors: Shah BD; Borate U; Kota VK; Zhang L; Peker D; Hathaway AR; Chavez JC
• Early Allogeneic Stem Cell Transplantation and Use of Asparaginase during Induction Chemotherapy Appear to Improve Otherwise Poor Outcomes in Adult T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) Patients: A Multi Institutional Review
  Volume: 126
  12/03/2015 Authors: Borate U; Hathaway AR; Peker D; Jackson BE; Kota VK; Shah BD; Zhang L; Jillella A; Arellano M; Heffner LT
• Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Single US Center Experience
  Volume: 126
  12/03/2015 Authors: Khoury HJ; Heffner LT; Arellano M; Jillella AP; Kota VK; Winton EF
• ATRA Availability on Formulary for the Treatment of APL Across Hospitals in the State of Georgia
  Volume: 126
  12/03/2015 Authors: Wheeler S; Puttagunta H; Surati M; Panjic E; Shah A; Arellano M; Jillella A; Kota VK
• Ruxolitinib As Sparing Agent for Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD)
  Volume: 126
  12/03/2015 Authors: Khoury HJ; Kota V; Arellano M; Bauer SL; Jillella AP; Langston A; Al-Kadhimi Z; DeFilipp Z; Kim AS; Winton EF
• Decreasing Early Deaths in Acute Promyelocytic Leukemia (APL) By Using a Simplified Treatment Algorithm and Establishing a Network with Academic and Community Centers in USA
  Volume: 126
  12/03/2015 Authors: Jillella A; Arellano M; Bashey A; Vidito SI; Stuart RK; Leung C; Sitchenko K; Gaddh M; Heffner LT; Kolhe RB
• Survival of Patients Diagnosed with Primary Refractory and Relapsed Acute Myeloid Leukemia from 2008-2012: A Single Institution Experience
  Volume: 126
  12/03/2015 Authors: Zeichner SB; Gleason S; Antun AG; Langston A; Heffner LT; Kota VK; Gaddh M; Arellano M
• Utility and impact of early t(15;17) identification by Fluorescence In Situ Hybridization (FISH) in clinical decision making for patients in Acute Promyelocytic Leukemia (APL).
  Int J Lab Hematol Volume: 37 Page(s): 515 - 520
  08/01/2015 Authors: Kolhe R; Mangaonkar A; Mansour J; Clemmons A; Shaw J; Dupont B; Walczak L; Mondal A; Rojiani A; Jillella A
• Clostridium difficile infection in adult patients with acute myeloid leukemia: Incidence, recurrence, and outcomes
  Volume: 33
  05/20/2015 Authors: Chintalapally R; Kukkadapu T; Parikh S; Mangaonkar AA; Boppidi HR; Kota V; Daram S
• Indoleamine 2,3-dioxygenase-1 expression in acute myeloid leukemia.
  Volume: 33
  05/20/2015 Authors: Mangaonkar AA; Mondal A; Jones K; Kota V; Savage N; Kolhe R
• Acute acalculous cholecystitis in patients with acute myeloid leukemia: Favorable outcomes with non-operative management
  Volume: 33
  05/20/2015 Authors: Kukkadapu T; Chintalapally R; Parikh S; Mangaonkar AA; Boppidi HR; Kota V; Daram S
• Prognostic significance of day+14 plasma cell count after initial induction therapy in Acute Myeloid Leukemia.
  Volume: 33
  05/20/2015 Authors: Mangaonkar AA; Chintalapally R; Mondal A; Kolhe RB; Kota V
• Acute facial paralysis and otomastoiditis as presenting symptoms of myeloid sarcoma.
  Otol Neurotol Volume: 36 Page(s): e104 - e106
  04/01/2015 Authors: Howell J; Segel J; Jajosky R; Savage NM; Fields B; Kota V; Mowry S
• Predicting early blast transformation in chronic-phase chronic myeloid leukemia: is immunophenotyping the missing link?
  Cancer Volume: 121 Page(s): 872 - 875
  03/15/2015 Authors: El Rassi F; Bergsagel JD; Arellano M; Gaddh M; Jillella A; Kota V; Heffner LT; Winton EF; Khoury HJ
• Is Karyotypically Normal (kn) Acute Myelogenous Leukemia (AML) Really Normal? Comprehensive Analysis of kn-AML Cases Demonstrating Utility of SNP Microarrays in Identifying New Regions of Oncogenic Potential in AML
  Volume: 95 Page(s): 356A - 356A
  02/01/2015 Authors: Kolhe RB; Chaubey A; Rojiani A; DuPont B; Fung E; Mondal A; Mangaonkar A; Cuevas J; Kwiatkowski K; Kota V
• Utility of Identifying Obesity Associated Methylation Changes in AML (Acute Myeloid Leukemia) Patients: Correlation With Clinical Outcome and Drug Response
  Volume: 95 Page(s): 356A - 356A
  02/01/2015 Authors: Kolhe RB; Deremer D; Rojiani A; Mondal A; Mangaonkar B; Kota V
• Utility of Identifying Obesity Associated Methylation Changes in AML (Acute Myeloid Leukemia) Patients: Correlation With Clinical Outcome and Drug Response
  Volume: 28 Page(s): 356A - 356A
  02/01/2015 Authors: Kolhe RB; Deremer D; Rojiani A; Mondal A; Mangaonkar A; Kota V
• Comprehensive Analysis of Karyotypically Normal Adult ALL (Acute Lymphoblastic Leukemia) Cases: Utility of SNP (Single Nucleotide Polymorphism) Microarrays in Identifying New Regions of Oncogenic Potential
  Volume: 28 Page(s): 455A - 455A
  02/01/2015 Authors: Chaubey A; DuPont B; Rojiani A; Cuevas J; Kwiatkowski K; Fung E; Kota V; Mondal A; Kolhe RB
• Is Karyotypically Normal (kn) Acute Myelogenous Leukemia (AML) Really Normal? Comprehensive Analysis of kn-AML Cases Demonstrating Utility of SNP Microarrays in Identifying New Regions of Oncogenic Potential in AML
  Volume: 28 Page(s): 356A - 356A
  02/01/2015 Authors: Kolhe RB; Chaubey A; Rojiani A; DuPont B; Fung E; Mondal A; Mangaonkar A; Cuevas J; Kwiatkowski K; Kota V
• Comprehensive Analysis of Karyotypically Normal Adult ALL (Acute Lymphoblastic Leukemia) Cases: Utility of SNP (Single Nucleotide Polymorphism) Microarrays in Identifying New Regions of Oncogenic Potential
  Volume: 95 Page(s): 455A - 455A
  02/01/2015 Authors: Chaubey A; DuPont B; Rojiani A; Cuevas J; Kwiatkowski K; Fung E; Kota V; Mondal A; Kolhe RB
• Volasertib for AML: clinical use and patient consideration.
  Onco Targets Ther Volume: 8 Page(s): 1761 - 1771
  01/01/2015 Authors: Hao Z; Kota V
• Pneumatosis Intestinalis in a Patient with Acute Promyelocytic Leukemia.
  Case Rep Hematol Volume: 2015 Page(s): 576042
  01/01/2015 Authors: Mangaonkar A; Mansour J; Keen R; Kukkadapu T; Chintalapally R; Kota V
• Day 30 Platelet Count As a Prognostic Marker of Survival in Acute Myeloid Leukemia
  BLOOD Volume: 124
  12/06/2014 Authors: Mangaonkar A; Mohsin J; Mansour J; Mondal A; Kolhe RB; Jillella A; Kota V; Puttagunta H
• Administration of anti-thymocyte globulin: a comparison of two protocols.
  Bone Marrow Transplant Volume: 49 Page(s): 1535 - 1537
  12/01/2014 Authors: Clemmons AB; Hartranft ME; Kota V; Pantin J; Awan FT; Salman H; Jillella AP
• Congestive heart failure during induction with anthracycline-based therapy in patients with acute promyelocytic leukemia.
  J Community Support Oncol Volume: 12 Page(s): 390 - 393
  11/01/2014 Authors: Kota V; Clemmons A; Chand A; Simmons J; Mansour J; Kolhe R; Jillella A
• Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
  Expert Rev Anticancer Ther Volume: 14 Page(s): 765 - 770
  07/01/2014 Authors: Hill BG; Kota VK; Khoury HJ
• A SIMPLE AND EFFECTIVE STRATEGY TO DECREASE EARLY DEATHS IN ACUTE PROMYELOCYTIC LEUKEMIA USING A STREAMLINED SET OF GUIDELINES PAIRED WITH EXPERT SUPPORT
  Volume: 99 Page(s): 298 - 298
  06/01/2014 Authors: Jillella A; Lane B; Rosshandler Y; Khoury JH; Arellano M; Natrajan K; Kolhe R; Bradley KT; Bashey A; Stuart R
• A successful model to decrease early deaths in acute promyelocytic leukemia (APL) through the use of a simplified algorithm and expert support.
  Volume: 32
  05/20/2014 Authors: Jillella AP; Kolhe RB; Natrajan K; Kota V
• Administration of Rabbit Anti-Thymocyte Globulin: Slowing Infusion Rate over a 4 Day Course with Aggressive Use of Pre-Medications May Decrease ATG Related Infusion Reactions
  Volume: 20 Page(s): S287 - S288
  02/01/2014 Authors: Clemmons AB; Hartranft ME; Kota V; Pantin J; Awan FT; Salman H; Jillella A
• Aggressive/Metastatic Prostatic Adenocarcinoma Cancer (PAC): Molecular Characterization by miRNA Expression Profiling May Explain Aggressive Behavior
  Volume: 94 Page(s): 464A - 464A
  02/01/2014 Authors: Kolhe R; Vasa P; Kavuri S; Lee J; Rahardja A; Rojiani A; Kota V
• Aggressive Prostatic Adenocarcinoma Cancer (PAC) in African American Males (AAM): Molecular Characterization by miRNA Expression Profiling May Explain Aggressive Behavior
  Volume: 94 Page(s): 241A - 241A
  02/01/2014 Authors: Kolhe R; Vasa P; Rahardja A; Kavuri S; Lee J; Rojiani A; Kota V
• Molecular Characterization of Acute Promyelocytic Leukemia (APML/APL) by miRNA Profiling: Deregulation of miRNA's Shedding New Insight into Disease Biology and Treatment Response
  Volume: 94 Page(s): 355A - 355A
  02/01/2014 Authors: Kolhe R; Vasa P; Rojiani A; Rahardja A; Kota V
• Aggressive Prostatic Adenocarcinoma Cancer (PAC) in African American Males (AAM): Molecular Characterization by miRNA Expression Profiling May Explain Aggressive Behavior
  Volume: 27 Page(s): 241A - 241A
  02/01/2014 Authors: Kolhe R; Vasa P; Rahardja A; Kavuri S; Lee J; Rojiani A; Kota V
• Molecular Characterization of Acute Promyelocytic Leukemia (APML/APL) by miRNA Profiling: Deregulation of miRNA's Shedding New Insight into Disease Biology and Treatment Response
  Volume: 27 Page(s): 355A - 355A
  02/01/2014 Authors: Kolhe R; Vasa P; Rojiani A; Rahardja A; Kota V
• Aggressive/Metastatic Prostatic Adenocarcinoma Cancer (PAC): Molecular Characterization by miRNA Expression Profiling May Explain Aggressive Behavior
  Volume: 27 Page(s): 464A - 464A
  02/01/2014 Authors: Kolhe R; Vasa P; Kavuri S; Lee J; Rahardja A; Rojiani A; Kota V
• Regions of Homozygosity (ROH) Identified in Cytogenetically Normal Cases of Acute Myelogenous Leukemia (AML) by High Resolution SNP Microarray
  Volume: 142
  01/01/2014 Authors: Chaubey A; Kolhe R; Bartel F; Kwiatkowski K; Fung E; Kota V; Rojiani A; DuPont B
• A Successful Model To Decrease Early and Preventable Deaths In Acute Promyelocytic Leukemia (APL) Through The Use Of a Simplified Algorithm and Expert Support In Experienced As Well As Smaller Leukemia Treatment Centers In The US
  Volume: 122
  11/15/2013 Authors: Jillella AP; Kolhe RB; Awan F; Natrajan K; Kota V
• Utility and Impact Of Early t(15;17) Identification By Fluorescence In Situ Hybridization (FISH) In Clinical Decision Making For Patients With Acute Promyelocytic Leukemia (APL)
  Volume: 122
  11/15/2013 Authors: Mangaonkar A; Kota V; Rojiani A; Jillella A; Kolhe RB
• Molecular Characterization By miRNA Expression Profiling in Acute Promyelocytic Leukemia (APL): deregulation Of Mirnas May Identify Patients At Risk Of Early Death
  Volume: 122
  11/15/2013 Authors: Kota V; Jillella A; Rojiani A; Arellano M; Kolhe RB
• Utility Of D-Dimer As a Marker For Differentiation Syndrome and Infections In Acute Promyelocytic Leukemia (APL)
  Volume: 122
  11/15/2013 Authors: Mansour J; Mangaonkar A; Zakharia Y; Chand AR; Jillella A; Kota V
• Utility of mir-21 Detection by Rapid Chromogenic in situ Hybridization (CISH) in the Diagnosis of Well and Moderately Differentiated (WD) Hepatocellular Carcinoma (HCC)
  AMERICAN JOURNAL OF CLINICAL PATHOLOGY Volume: 140 Page(s): 64 - 64
  09/01/2013 Authors: Rahardja A; Liles G; Vasa P; Rojiani A; Kota V; Kolhe R; Kalra K
• Differential miRNA Expression in Malignant Melanoma (MM), Dysplastic Nevus With Atypia (DN) and Benign Nevus (BN) and its Clinical Applications
  AMERICAN JOURNAL OF CLINICAL PATHOLOGY Volume: 140 Page(s): 97 - 97
  09/01/2013 Authors: Vasa PS; Rahardja A; Kota V; Kolhe R
• Congestive heart failure (CHF) in acute myeloid leukemia patients during induction
  Volume: 31
  05/20/2013 Authors: Raval P; Kota V; Zakharia Y; Carter G; Christopherson K; Awan FT; Pantin JM; Jillella AP
• Decreasing early mortality (30-day) in APL patients with use of streamlined treatment guidelines and support from core group of experts.
  Volume: 31
  05/20/2013 Authors: Jillella AP; Awan FT; Pantin JM; Kolhe RB; Kota V
• CD20+Plasma Cell Myeloma (PCM): Molecular Characterization by miRNA Profiling Leads to New Insights into Disease Biology and Clinico-Pathological Behavior
  Volume: 93 Page(s): 337A - 338A
  02/01/2013 Authors: Kolhe R; Rojiani A; Jillella A; Kota V
• Plasmablastic Lymphoma (PBL): Molecular Characterization by miRNA Expression Profiling
  Volume: 26 Page(s): 337A - 337A
  02/01/2013 Authors: Kolhe R; Rojiani A; Jillella A; Kota V
• Plasmablastic Lymphoma (PBL): Molecular Characterization by miRNA Expression Profiling
  Volume: 93 Page(s): 337A - 337A
  02/01/2013 Authors: Kolhe R; Rojiani A; Jillella A; Kota V
• Utility and Impact of Early t(15:17) Identification by Fluorescence In Situ Hybridization (FISH) in Clinical Decision Making for Referral Patients in Acute Promyelocytic Leukemia (APML)
  Volume: 93 Page(s): 337A - 337A
  02/01/2013 Authors: Kolhe R; Rojiani A; Jillella A; Kota V; Walczak L; Shaw J; DuPont B
• CD20+Plasma Cell Myeloma (PCM): Molecular Characterization by miRNA Profiling Leads to New Insights into Disease Biology and Clinico-Pathological Behavior
  Volume: 26 Page(s): 337A - 338A
  02/01/2013 Authors: Kolhe R; Rojiani A; Jillella A; Kota V
• A Multicenter Analysis of Intermediate-Dose Cyclophosphamide Versus Plerixafor and Granulocyte Colony Stimulating Factor for PB Progenitor Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Chemotherapies
  Volume: 19 Page(s): S182 - S183
  02/01/2013 Authors: Awan FT; Kochuparambil S; Craig M; Cumpston A; Leadmon S; DeRemer D; Watkins K; Pantin J; Kota V; Jillella A
• Utility and Impact of Early t(15:17) Identification by Fluorescence In Situ Hybridization (FISH) in Clinical Decision Making for Referral Patients in Acute Promyelocytic Leukemia (APML)
  Volume: 26 Page(s): 337A - 337A
  02/01/2013 Authors: Kolhe R; Rojiani A; Jillella A; Kota V; Walczak L; Shaw J; DuPont B
• Improving the Accuracy of BCR-ABL Transcript Quantitation: Pitfalls of Using a Common Standard for b3a2 and b2a2 Transcripts
  Volume: 120
  11/16/2012 Authors: Zhang H; Fletcher L; Patel N; Bryant S; Li H; Kutlar F; Jillella AP; Kota V; Clair B; Kutlar A
• Intermediate-Dose Cyclophosphamide Versus Plerixafor and Granulocyte Colony Stimulating Factor (G-CSF) for Peripheral Blood Progenitor Cell (PBPC) Mobilization in Patients with Multiple Myeloma (MM) Treated with Novel Induction Chemotherapies - A Multicenter Analysis
  Volume: 120
  11/16/2012 Authors: Awan F; Kochuparambil ST; Craig M; Cumpston A; Leadmon S; Watkins K; Deremer D; Pantin J; Kota V; Jillella AP
• A Network of Treatment Centers and Standardisation of Treatment Protocol Leads to Reduction in Mortality in Acute Promyelocytic Leukemia (APL)
  Volume: 120
  11/16/2012 Authors: Jillella AP; Awan F; Kolhe RB; Pantin JM; Morrison DD; Kota V
• miRNA Expression Profiling of Plasmablastic Lymphoma: Up-regualtion of mir-196a Shedding New Insight Into Disease Biology and aggressive Clinicopathologic Behavior
  Volume: 138 Page(s): A214 - A214
  11/01/2012 Authors: Kolhe R; Rojiani A; Jillella A; Kota V
• miRNA Expression Profiling of CD20+Plasma Cell Myeloma (PCM): Up-regualtion of mir-155 Shedding New Insight Into Disease Biology and Clinicopathologic Behavior
  Volume: 138 Page(s): A339 - A339
  11/01/2012 Authors: Kolhe R; Rojiani A; Jillella A; Kota V
• Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.
  Biol Blood Marrow Transplant Volume: 18 Page(s): 1128 - 1135
  07/01/2012 Authors: Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D
• Spectral fluctuation and 1/f noise in the energy level statistics of interacting trapped bosons.
  Phys Rev E Stat Nonlin Soft Matter Phys Volume: 85 Page(s): 061119
  06/01/2012 Authors: Roy K; Chakrabarti B; Biswas A; Kota VKB; Haldar SK
• A simple but effective model to decrease early deaths in acute promyelocytic leukemia (APL).
  Volume: 30
  05/20/2012 Authors: Jillella AP; Sadek I; Morrison D; Natrajan K; Awan FT; Kolhe R; Kota V
• miRNA expression profiling of CD20+plasma cell myeloma (PCM): Upregulation of miR-155 shedding new insight into disease biology and clinicopathologic behavior.
  Volume: 30
  05/20/2012 Authors: Kolhe R; Jillella AP; Natrajan K; Awan FT; Manaloor E; Kota V
• CLINICAL PRACTICE GUIDELINE FOR THE TREATMENT OF BK-VIRUS INDUCED HEMORRHAGIC CYSTITIS IN THE POST-ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT SETTING
  Volume: 18 Page(s): S329 - S329
  02/01/2012 Authors: Morrison D; Kochuparambil T; DeRemer D; Kota V; Jillela A; Awan F
• Chromosome 7 Abnormalities in Allogeneic Transplantation for AML and MDS
  Volume: 118 Page(s): 892 - 893
  11/18/2011 Authors: Kota V; Saliba RM; Bayraktar UD; Beitinjaneh A; Chen JJ; Parmar S; Giralt SA; Rondon G; Ciurea SO; Kebriaei P
• Intermediate- Versus Low-Dose Cyclophosphamide and Granulocyte Colony Stimulating Factor for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Chemotherapies - A Multicenter Analysis
  Volume: 118 Page(s): 146 - 146
  11/18/2011 Authors: Hamadani SM; Kochuparambil ST; Osman S; Speir E; Craig M; Deremer D; Cumpston A; Morrison DD; Leadmon S; Sterling K
• IMPROVING AUTOLOGOUS TRANSPLANT OUTCOMES IN THE ELDERLY
  Volume: 17 Page(s): S200 - S200
  02/01/2011 Authors: Parikh JR; Kota V; Awan FT; Jillella AP
• Acute leukemia with PICALM-MLLT10 fusion gene: diagnostic and treatment struggle.
  Cancer Genet Cytogenet Volume: 202 Page(s): 129 - 132
  10/15/2010 Authors: Savage NM; Kota V; Manaloor EJ; Kulharya AS; Pierini V; Mecucci C; Ustun C
• Pancreatitis following administration of iodixanol in patients on hemodialysis: a pilot study.
  Clin Nephrol Volume: 73 Page(s): 381 - 384
  05/01/2010 Authors: Kheda M; Brenner L; Riggans D; Kota V; Szerlip HM